<DOC>
	<DOC>NCT01663740</DOC>
	<brief_summary>This observational study will compare spermatogenesis in male adult renal transp lant recipients receiving valganciclovir versus untreated matched controls. Data will be collected from each patient for up to 52 weeks post transplant.</brief_summary>
	<brief_title>An Observational Study on Spermatogenesis in Male Renal Transplant Recipients Receiving Valcyte (Valganciclovir) Versus Untreated Matched Controls</brief_title>
	<detailed_description />
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<mesh_term>Valganciclovir</mesh_term>
	<criteria>Male patient, &gt;/= 20 to &lt;/= 50 years of age First renal transplant Patient eligible to receive at least 100 days or up to 200 days valganciclovir prophylaxis as determined by the treating physician in accordance with the product information (Cohort A only) or the patient is not expected to require any valganciclovir prophylaxis (Cohort B only) posttransplant Patient has no history of known infertility Patient is willing to provide sperm samples Patient agrees to use a barrier contraceptive throughout the study or for at least 90 days after cessation of valganciclovir treatment Prior ganciclovir or valganciclovir within 3 months of enrollment Organ transplant other than kidney Has received an investigational new drug in the 3 months prior to transplant Receiving an alkylating agent or other medications known to affect spermatogenesis</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>